Isomorphic Labs aims to design cancer drugs with AI, plans human trials soon
Google DeepMind spinoff Isomorphic Labs, led by CEO Demis Hassabis and President Max Jaderberg, is using its AlphaFold-derived drug design engine to develop novel cancer, immune, and inflammatory disease treatments. The company has research partnerships with Novartis, Johnson & Johnson, and Eli Lilly, and has built a clinical development team in Boston in preparation for human trials, though…
Key points
- Isomorphic Labs uses AlphaFold-based engine to design novel cancer and immune drugs
- Partnerships with Novartis, Johnson & Johnson, Eli Lilly; clinical team built in Boston
- OpenAI and Anthropic now competing with own drug discovery models and partnerships
The story so far
3 episodes →- Isomorphic Labs aims to design cancer drugs with AI, plans human trials soonthis story
Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
businessinsider.com · 30 October 2026Loading the full article…
This text was published by businessinsider.com and written by Tom Carter. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Research
All →- Leo de Moura says AI agents are making formal verification practical · 1 src
- Anthropic's unreleased Claude AI finds critical Linux kernel flaw CVE-2026-98432 · 1 src
- Anthropic opens biology lab with AI agents to find uncharacterized enzyme system · 2 src
- Schmidt Sciences names five MIT faculty 2026 AI2050 Fellows · 1 src
- IDPForge presents deep learning method for intrinsically disordered proteins · 1 src
Comments
via GitHub Discussions